In 365 patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane, trastuzumab botidotin extended median PFS versus trastuzumab emtansine (11.1 v 4.4 months; HR 0.39). Overall survival immature; ocular toxicity common.
RCTn = 365
Zhang et al. Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial